Mental health is a significant yet overlooked aspect of inflammatory bowel disease (IBD) patient care, with challenges in determining optimal treatments and psychological health resources. The most common psychological conditions in patients with IBD are anxiety and depression. The increased prevalence of these mental disorders appeals to mental screening of each person diagnosed with IBD at initial consultation. There are simple and clinically viable methods available to screen for mental problems. Psychological methods may be as or even more significant as a therapeutic modality. Herein we discuss the three major areas of psychological co-morbidity in IBD: (1) the prevalence and risk factors associated with anxiety and depression disorders for patients with IBD; (2) diagnosis of psychological disorders for patients with IBD; (3) treatment with patients with IBD and mental disorders. The gastroenterologists are encouraged to screen and treat these patients with IBD and mental disorders, which may improve outcomes.
Nonalcoholic fatty liver disease (NAFLD) is a major health threat around the world and is characterized by dysbiosis. Primary bile acids are synthesized in the liver and converted into secondary bile acids by gut microbiota. Recent studies support the role of bile acids in modulating dysbiosis and NAFLD, while the mechanisms are not well elucidated. Dysbiosis may alter the size and the composition of the bile acid pool, resulting in reduced signaling of bile acid receptors such as farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5). These receptors are essential in lipid and glucose metabolism, and impaired bile acid signaling may cause NAFLD. Bile acids also reciprocally regulate the gut microbiota directly via antibacterial activity and indirectly via FXR. Therefore, bile acid signaling is closely linked to dysbiosis and NAFLD. During the past decade, stimulation of bile acid receptors with their agonists has been extensively explored for the treatment of NAFLD in both animal models and clinical trials. Early evidence has suggested the potential of bile acid receptor agonists in NAFLD management, but their long-term safety and effectiveness need further clarification.
Background: Functional dyspepsia (FD) is most often a meal-induced syndrome. Studies using resting-state functional magnetic resonance imaging (rs-fMRI) reported abnormal connectivity in areas related to pain processing in FD. However, only a few studies have attempted to determine how meal ingestion affects the brain's working patterns. Through rs-fMRI, this study observed how meal ingestion affected brain regions related to visceral hypersensitivity and emotional response networks in FD patients.Methods: A total of 30 FD patients and 32 healthy controls (HC) were enrolled and underwent clinical investigations. Rs-fMRI was performed twice after a 4-h fast and 50 min after a meal. The mean functional connectivity strength (FCS) values were extracted from brain regions with significant differences to show the trend of changes related to meal ingestion after FCS analyses.Results: Depression, anxiety, sleep disturbances, and weight loss were more common in FD patients (P ≤ 0.001). Compared with HCs (corrected cluster P-value < 0.05), FD patients had significantly higher FCS in the right middle frontal gyrus before meals and higher meal-induced FCS in the left postcentral gyrus. HCs had greater meal-induced activation in the right precuneus and anterior cingulate cortex. FD patients had a decreasing trend in the right inferior frontal gyrus compared to the increasing trend in HCs. We only found anxiety to be negatively correlated with FCS in the right inferior frontal gyrus in FD (r = −0.459, p = 0.048, uncorrected).Conclusions: In this study, we discovered that FD patients have different perceptual and emotional responses to food intake in defined brain areas, providing promising impetus for understanding pathogenic brain mechanisms in FD.
Antigenic peptide-based mRNA vaccines have been explored for immunotherapeutic use in various types of cancer because of their advantages in activating durable and specific immune responses. However, their role in modulating tumor metastasis is still unclear. Here, we identify a conserved linear epitope-based peptide, Ma3P, located in the proteolytic region of major histocompatibility complex (MHC) class I-related chain A (MICA) α3 and further design mCM10-L, an mRNA vaccine that encodes the carrier protein CRM197 and 10 tandem repeats of Ma3P. We demonstrate that vaccination with mCM10-L induces the production of specific antibodies that block MICA/B α1/2 shedding, activate CD8+ T cells and natural killer (NK) cells, and significantly inhibit MICA/B+ tumor metastasis in mice. Furthermore, mCM10-L stimulation triggers the production of specific antibodies to promote MICA/B-mediated immune killing in an in-vitro-interacting human organoid model and humanized mice. Our results indicate the potential clinical application prospects of the mCM10-L vaccine.
There are limited data regarding the morphology, histopathology, and anatomical distribution of sporadic colorectal polyps in Chinese patients. We evaluated these characteristics of sporadic polyps to guide the endoscopic detection and excision of colorectal polyps. This was a retrospective single-center observational study involving 7381 patients with sporadic colorectal polyps. All polyps were removed endoscopically. The morphology and histopathology of polyps were evaluated according to the Paris classification and the World Health Organization classification, respectively. A total of 22,174 polyps removed endoscopically from 7322 patients were included. In the sigmoid colon, 24.70% of colorectal polyps occurred, followed by the transverse colon (18.58%) in frequency. 0-Is type polyps accounted for 60.60% of all sporadic colorectal polyps. Polyps with 0-Ip, 0-Isp, and 0-IIa types were frequently found in the sigmoid colon, but laterally spreading lesions usually occurred in the ascending colon (24.61%) and rectum (20.51%). Irrespective of the Paris classification and anatomical location, as the polyps enlarge, the proportion of adenomatous polyps gradually increases while the proportion of serrated lesions decreases. Polyps with size ≥1 cm located in the left-sided colon were more likely to have villous/tubulovillous or high-grade dysplasia histology than those located in the right-sided colon, and about 1% of them were demonstrated with adenocarcinoma. Sigmoid colon should be detected adequately during colonoscopy, and polyps with size ≥1 cm should be treated carefully, especially in the left-sided colon.
Individuals with Inflammatory Bowel Disease (IBD) often suffer from psychological comorbidities, including symptoms of anxiety and depression, which contribute to a substantial impairment in quality of life (QOL). The potential benefits of online mindfulness interventions for IBD remain unexplored. Study 1 (cross-sectional survey): To establish correlations between the severity of depression and anxiety and the QOL in IBD patients. Study 2 (pilot study): To evaluate the feasibility and preliminary effects of a mobile-delivered mindfulness intervention on psychological symptoms and QOL/sleep quality. Study 1: Anxiety, depression and QOL were measured using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Short Health Scale (SHS) respectively. They were assessed in 484 IBD patients. Regression analyses determined associations. Study 2: A randomized parallel design tested the Online MINdfulness-based stress reduction with Daily EXercise (MINDEX) program vs an active control (IBD education video) over 2 months. Sleep quality was measured using Pittsburgh Sleep Quality Index (PSQI). Feasibility was assessed via retention (30/36 intervention vs. 22/36 control completers) and all completion rates (25%); Preliminary effects via GAD-7/PHQ-9/SHS/PSQI changes. Study 1: More than 80% of the patients had severe anxiety or depression. The study revealed a significant association between increased GAD-7 scores and SHS scores, with an R2 of 0.43 and coefficient of 12.6 (95% CI 9.4–15.7) for UC (Ulcerative Colitis) and R2 of 0.27 with a coefficient of 10.4 (95% CI 8.8–12.1) for CD (Crohn’s Disease). Similarly, higher PHQ-9 scores correlated significantly with higher SHS scores, with an R2 of 0.37 and a coefficient of 9.2 (95% CI 6.5–11.8) for UC, and an R2 of 0.22 with a coefficient of 7.2 (95% CI 5.9–8.6) for CD. Study 2: 30 MINDEX patients completed the intervention, and 22 control patients completed the control program. At two-month follow-up, no statistically significant differences were observed in GAD-7, PHQ-9, SHS or PSAI scores between the MINDEX group and the control group (0.052 < P < 0.908). Study 1: Our findings indicate strong associations between psychological symptoms and QOL in IBD, while causal relationships require Longitudinal investigation. Study 2: While feasibility to implement this pilot trial found no significant short-term benefits of MINDEX on anxiety, depression, QOL, or PSQI over the 2-month study period. Larger trials with longer follow-up are needed to evaluate efficacy. ClinicalTrials.gov NCT04939948, Clinical Trial Registry June 17, 2021.